Mdr-1 ribozyme in the reversal of multidrug resistance in human ovarian cancer.
- Author:
Xiao-kui YANG
1
;
Hui XING
;
Qing-lei GAO
;
Wei WANG
;
Su-fang WU
;
Yun-ping LU
;
Shi-xuan WANG
;
Ding MA
Author Information
- Publication Type:Journal Article
- MeSH: ATP-Binding Cassette, Sub-Family B, Member 1; analysis; genetics; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; drug therapy; metabolism; RNA, Catalytic; therapeutic use; RNA, Messenger; analysis
- From: Chinese Journal of Oncology 2003;25(5):425-428
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the mechanism of multidrug resistance and its reversal by mdr-1 ribozyme in human ovarian cancer.
METHODSThe expression of mdr-1 and p-glycoprotein (p-gp) was studied by confocal laser microscope (Confocal), RT-PCR and Western blot analysis in adriamycin-resistant human ovarian cancer cell line (A2780/ADM) and adriamycin-sensitive one (A2780). The mdr-1 ribozyme was transfected into the A2780/ADM by Lipofectamine 2000 to overcome the multidrug resistance in ovarian cancer.
RESULTSThe expression of mdr-1 mRNA and p-gp in A2780/ADM was significantly higher than that in A2780. The expression of mdr-1 mRNA and p-gp in A2780/ADM was lowered after being transfected by mdr-1 ribozyme.
CONCLUSIONMultidrug resistance of A2780/ADM, possibly being caused by overexpression of mdr-1 gene, can be partially reversed by mdr-1 ribozyme.
